CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer’s Disease (CTAD) Conference – ChiesiVentures

November 7, 2023

CuraSen Presents Late-Breaking Phase 2 Data with CST-2032/CST-107 at Clinical Trials in Alzheimer’s Disease (CTAD) Conference

Oct 24, 2023

https://www.curasen.com/wp-content/uploads/2023/10/Poster-034-Harrison-CTAD-2023-FINAL2.pdf

Related articles

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants